Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The company had revenue of $294.45 million for the quarter, compared to analyst estimates of $12.00 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. Lexicon Pharmaceuticals’s revenue was up 4124.5% on a year-over-year basis.
Shares of LXRX stock traded down $0.36 during midday trading on Friday, reaching $3.52. 1,316,800 shares of the company traded hands, compared to its average volume of 1,292,482. Lexicon Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $9.15. The firm’s 50 day simple moving average is $3.52 and its two-hundred day simple moving average is $4.21. The firm has a market cap of $419.77 million, a PE ratio of -3.09 and a beta of 0.95.
In related news, Director Christopher J. Sobecki acquired 25,000 shares of the stock in a transaction dated Monday, September 16th. The stock was bought at an average cost of $2.55 per share, with a total value of $63,750.00. Following the purchase, the director now directly owns 112,493 shares of the company’s stock, valued at $286,857.15. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christopher J. Sobecki acquired 99,249 shares of the stock in a transaction dated Friday, September 13th. The shares were bought at an average cost of $2.41 per share, with a total value of $239,190.09. Following the completion of the purchase, the director now directly owns 13,645 shares in the company, valued at $32,884.45. The disclosure for this purchase can be found here. Insiders have bought a total of 255,749 shares of company stock valued at $578,510 over the last three months. Corporate insiders own 6.40% of the company’s stock.
A number of research firms have recently issued reports on LXRX. Stifel Nicolaus downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from $10.00 to $4.00 in a research report on Monday, July 29th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 5th. Wedbush reiterated a “buy” rating and set a $17.00 price target on shares of Lexicon Pharmaceuticals in a research report on Friday, October 4th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Saturday. Finally, Gabelli upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $6.45.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Street Name
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.